FINWIRES · TerminalLIVE
FINWIRES

研究快讯:Host Hotels & Resorts Inc. 第一季度业绩指引上调,每间可供出租客房收入增长势头持续

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:HST公布2026年第一季度营收为16亿美元(同比增长3.2%),超出市场预期4900万美元;每股FFO为0.67美元(同比增长4.7%),超出市场预期0.06美元。可比总RevPAR同比增长4.6%至418.20美元,酒店EBITDA利润率提升70个基点至32.7%,入住率提升40个基点至70.3%,主要得益于迈阿密(+14.9%)、旧金山/圣何塞(+25.6%)和杰克逊维尔(+16.1%)的强劲表现。我们相信,HST与凯悦和万豪的战略性翻新项目,包括预计于2026年获得的1900万美元运营担保,将有助于提升长期资产价值和竞争优势。管理层上调了2026财年业绩预期,预计每股FFO为2.10-2.16美元,同店RevPAR增长率为3.5%-5.0%。我们预计,FIFA世界杯赛事和特别活动将持续推动团体预订量小幅增长。HST拥有稳健的资产负债表,总流动资金达34亿美元,其中包括17亿美元现金,这为1.75亿至2.1亿美元的转型资本投资提供了灵活性。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661